Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$307.37|
|52 Week High||US$144.36|
|52 Week Low||US$327.32|
|1 Month Change||11.44%|
|3 Month Change||50.65%|
|1 Year Change||108.70%|
|3 Year Change||453.52%|
|5 Year Change||914.42%|
|Change since IPO||2,973.70%|
Recent News & Updates
|RGEN||US Life Sciences||US Market|
Return vs Industry: RGEN exceeded the US Life Sciences industry which returned 56.4% over the past year.
Return vs Market: RGEN exceeded the US Market which returned 35.3% over the past year.
Stable Share Price: RGEN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: RGEN's weekly volatility (4%) has been stable over the past year.
About the Company
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company’s chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes.
Repligen Fundamentals Summary
|RGEN fundamental statistics|
Is RGEN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RGEN income statement (TTM)|
|Cost of Revenue||US$207.19m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||1.82|
|Net Profit Margin||19.65%|
How did RGEN perform over the long term?See historical performance and comparison
Is Repligen undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: RGEN ($323.26) is trading above our estimate of fair value ($144.9)
Significantly Below Fair Value: RGEN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: RGEN is poor value based on its PE Ratio (177.8x) compared to the US Life Sciences industry average (53.1x).
PE vs Market: RGEN is poor value based on its PE Ratio (177.8x) compared to the US market (17.9x).
Price to Earnings Growth Ratio
PEG Ratio: RGEN is poor value based on its PEG Ratio (8.8x)
Price to Book Ratio
PB vs Industry: RGEN is overvalued based on its PB Ratio (11.1x) compared to the US Life Sciences industry average (6.1x).
How is Repligen forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RGEN's forecast earnings growth (20.3% per year) is above the savings rate (2%).
Earnings vs Market: RGEN's earnings (20.3% per year) are forecast to grow faster than the US market (15% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: RGEN's revenue (17.1% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: RGEN's revenue (17.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RGEN's Return on Equity is forecast to be low in 3 years time (9.2%).
How has Repligen performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RGEN has high quality earnings.
Growing Profit Margin: RGEN's current net profit margins (19.7%) are higher than last year (10.2%).
Past Earnings Growth Analysis
Earnings Trend: RGEN's earnings have grown significantly by 38.5% per year over the past 5 years.
Accelerating Growth: RGEN's earnings growth over the past year (223%) exceeds its 5-year average (38.5% per year).
Earnings vs Industry: RGEN earnings growth over the past year (223%) exceeded the Life Sciences industry 56.9%.
Return on Equity
High ROE: RGEN's Return on Equity (6.2%) is considered low.
How is Repligen's financial position?
Financial Position Analysis
Short Term Liabilities: RGEN's short term assets ($983.8M) exceed its short term liabilities ($332.3M).
Long Term Liabilities: RGEN's short term assets ($983.8M) exceed its long term liabilities ($80.6M).
Debt to Equity History and Analysis
Debt Level: RGEN's debt to equity ratio (15.6%) is considered satisfactory.
Reducing Debt: RGEN's debt to equity ratio has reduced from 57% to 15.6% over the past 5 years.
Debt Coverage: RGEN's debt is well covered by operating cash flow (33.4%).
Interest Coverage: RGEN's interest payments on its debt are well covered by EBIT (10.9x coverage).
What is Repligen current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate RGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RGEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RGEN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RGEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Tony Hunt (57 yo)
Mr. Anthony J. Hunt, also known as Tony, has been the Chief Executive Officer and President of Repligen Corporation since May 21, 2015. Mr. Hunt served as Secretary of Repligen Corporation. He served as Ch...
CEO Compensation Analysis
Compensation vs Market: Tony's total compensation ($USD5.07M) is below average for companies of similar size in the US market ($USD11.36M).
Compensation vs Earnings: Tony's compensation has been consistent with company performance over the past year.
Experienced Management: RGEN's management team is considered experienced (4.5 years average tenure).
Experienced Board: RGEN's board of directors are considered experienced (5.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: RGEN insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.7%.
Repligen Corporation's employee growth, exchange listings and data sources
- Name: Repligen Corporation
- Ticker: RGEN
- Exchange: NasdaqGS
- Founded: 1981
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$16.898b
- Shares outstanding: 54.98m
- Website: https://www.repligen.com
Number of Employees
- Repligen Corporation
- Building 1
- Suite 100
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/27 22:54|
|End of Day Share Price||2021/09/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.